Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01409811 · ClinicalTrials.gov registry record · NA
Biomarkers in Tissue Samples From Patients With Newly Diagnosed Breast Cancer Treated With Zoledronic Acid
A NA study, sponsored by City of Hope Medical Center.
- Terminated
- Registry status
- NA
- Development phase
- 9
- Enrollment target
NCT01409811 is a NA study that was terminated before completion, run by City of Hope Medical Center. The registered enrollment target is 9 participants.
The verdict
NCT01409811, a NA study, was terminated before completion, sponsored by City of Hope Medical Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 9 participants
- Enrollment target
Study Summary
This pilot clinical trial studies biomarkers in tissue samples from patients with newly diagnosed breast cancer treated with zoledronic acid (ZA). Studying samples of tumor tissue in the laboratory from patients receiving ZA may help doctors learn more about the effects of ZA on cells. It may also help doctors understand how well patients respond to treatment.
Interventions
- OTHER laboratory biomarker analysis
- PROCEDURE therapeutic conventional surgery
- DRUG zoledronic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2012-09-14 |
| Est. Completion | 2015-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01409811
The ClinicalTrials.gov registry entry for NCT01409811 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT01409811 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01409811 about?
NCT01409811 is a clinical study titled "Biomarkers in Tissue Samples From Patients With Newly Diagnosed Breast Cancer Treated With Zoledronic Acid". This pilot clinical trial studies biomarkers in tissue samples from patients with newly diagnosed breast cancer treated with zoledronic acid (ZA). Studying samples of tumor tissue in the laboratory from patients receiving ZA may help doctors learn more about the effects of ZA on cells. It may also h...
What is the current status of trial NCT01409811?
This trial is currently terminated. It is a NA study. The enrollment target is 9 participants. The study started on 2012-09-14. Estimated completion is 2015-02.
What interventions are being tested in trial NCT01409811?
The interventions under investigation include: laboratory biomarker analysis (OTHER), therapeutic conventional surgery (PROCEDURE), zoledronic acid (DRUG).
Who is sponsoring clinical trial NCT01409811?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.